(S)-2-(1-hydroxy-2-N-methylamino-ethyl)-pyridine | 566947-81-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-2-(1-hydroxy-2-N-methylamino-ethyl)-pyridine
• 英文别名: (S)-1-(2-pyridyl)-2-(methylamino)ethanol；(1S)-2-(methylamino)-1-pyridin-2-ylethanol
• CAS: 566947-81-7
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: USOSIWSZNNWAQV-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-(1-hydroxy-2-N-methylamino-ethyl)-pyridine 、 N-(4-chlorobenzyl)-9-(chloromethyl)-1-methyl-2,7-dioxo-2,3-dihydro-1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamide 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-[(4-chlorophenyl)methyl]-7-[[[(2S)-2-hydroxy-2-pyridin-2-ylethyl]-methylamino]methyl]-4-methyl-3,10-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxamide
  参考文献：
  名称：

  The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

  摘要：

  Discovery efforts were focused on identifying a non-nucleoside antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA polymerase inhibition and in vitro antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.094
• 作为产物：
  描述：

  2-溴吡啶 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 (1S,2S)-(+)-N-对甲苯磺酰基-1,2-二苯基乙二胺 甲酸 、 异丙基氯化镁 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.75h， 生成 (S)-2-(1-hydroxy-2-N-methylamino-ethyl)-pyridine
  参考文献：
  名称：

  Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols

  摘要：

  As part of medicinal chemistry efforts we found it necessary to develop general syntheses of highly enantiomerically enriched 1-aryl-2-chloroethanols and 1-aryl-2-methylaminoethanols. A survey of literature methods suggested that a truly general approach had not yet been reported, encouraging us to undertake the development of such a methodology. This study describes the design, development, and reduction to practice of a general synthesis of chiral 1-aryl-2-chloroethanols and the transformation of these entities to highly enantiomerically enriched 1-aryl-2-methylaminoethanols. Of particular importance were observations of the impact of solvent and the method of catalyst preparation on the yield and enantiomerical excess of chlorohydrins prepared via Noyori transfer hydrogenations of aryl-chloromethyl ketones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.017

文献信息

• [EN] PROCESS TO PRODUCE ENANTIOMERICALLY ENRICHED 1-ARYL- AND 1-HETEROARYL-2-AMINOETHANOLS<br/>[FR] PROCEDE DE PREPARATION D'1-ARYL- ET D'1-HETEROARYL-2-AMINOETHANOLS ENRICHIS EN ENANTIOMERES
  申请人：UPJOHN CO

  公开号：WO2004085414A1

  公开（公告）日：2004-10-07

  The invention relates to a method of preparing enantiomerically enriched amino alcohols of Formula (I) wherein the variable R1, R2, and R3 are defined herein.

  这项发明涉及一种制备式(I)的对映体富集氨基醇的方法，其中变量R1、R2和R3在此处被定义。
• 7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: Synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase
  作者：Scott D. Larsen、Zhijun Zhang、Brian A. DiPaolo、Peter R. Manninen、Douglas C. Rohrer、Michael J. Hageman、Todd A. Hopkins、Mary L. Knechtel、Nancee L. Oien、Bob D. Rush、Francis J. Schwende、Kevin J. Stefanski、Janet L. Wieber、Karen F. Wilkinson、Kathyrn M. Zamora、Michael W. Wathen、Roger J. Brideau

  DOI：10.1016/j.bmcl.2007.05.010

  日期：2007.7

  We report a new class of non-nucleoside antivirals, the 7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides, some of which possess remarkable potency versus a broad spectrum of herpesvirus DNA polymerases and excellent selectivity compared to human DNA polymerases. A critical factor in the level of activity is hypothesized to be conformational restriction of the key 2-aryl-2-hydroxyethylamine sidechain

  我们报告了一种新型的非核苷类抗病毒药，即7-氧代-4,7-二氢噻吩并[3,2-b]吡啶-6-羧酰胺，其中一些具有显着的效力，与广谱的疱疹病毒DNA聚合酶相比，具有出色的杀伤力。与人类DNA聚合酶相比具有更高的选择性。假定活性水平中的关键因素是关键的2-芳基-2-羟基乙胺侧链被相邻的甲基构象限制。
• Process to produce enantiomerically enriched 1-aryl-and 1-heteroaryl-2-aminoethanols
  申请人：Pfizer, Inc.

  公开号：US20040236151A1

  公开（公告）日：2004-11-25

  The invention relates to a method of preparing enantiomerically enriched amino alcohols of Formula I 1 wherein the variable R1, R2, and R3 are defined herein.

  本发明涉及一种制备对映体富集的式I1的氨基醇的方法，其中变量R1、R2和R3在此处定义。
• ANTIVIRAL COMPOUNDS
  申请人：——

  公开号：US20040242884A1

  公开（公告）日：2004-12-02

  The invention provides a compound of formula I: 1 wherein G, R 2 , R 3 , and R 4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpes virus infection using such compounds or salts.

  本发明提供了一种I式化合物：1，其中G，R2，R3和R4具有规范中定义的任何值，或其药学上可接受的盐，以及用于制备这种化合物或盐的有用中间体和过程，以及使用这种化合物或盐预防或治疗疱疹病毒感染的方法。
• Antiviral compounds
  申请人：Larsen Scott D.

  公开号：US06852731B2

  公开（公告）日：2005-02-08

  The invention provides a compound of formula I: wherein G, R 2 , R 3 , and R 4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

  该发明提供了化合物I的公式：其中G，R2，R3和R4具有规范中定义的任何值或其药学上可接受的盐，以及用于制备这样的化合物或盐的中间体和过程，以及使用这样的化合物或盐预防或治疗疱疹病毒感染的方法。